CGRP Forum is made possible thanks to support from AbbVie, Organon and Pfizer, all of whom have no influence or control over editorial content. More information is available here »

ECLIPSE data support atogepant for acute migraine treatment Redefining a migraine day to reduce variability Should patients switch to a CGRP mAb or a gepant?UNION study confirms ubrogepant efficacy with CGRP mAbs Norwegian registry reports effects of CGRP mAb exposure during pregnancy CGRP mAb experience at a major UK centre Breaking down access barriers to newer preventive therapies Best responders to CGRP mAbs need treatment persistence

Meetings

Conferences for 2025

19th European Headache Congress
3-6 December 2025
Lisbon, Portugal
https://headache-congress.org

Educational Partners and Supporters

This program is funded in part via an independent educational grant from AbbVie.

Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.

Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2025 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach | Educational Partners and Supporters |